Kelly Miller, MD
Medical Oncology · Kettering, OHNPI 1245596626
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,143 of the $1,282 with a category attached, or 89.2%. It is spread thinly across 22 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $513 and has fallen 80.5% since, to $100 in 2025. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 83 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$220
- Johnson & Johnson$194
- Novartis$154
- Bristol Myers Squibb$138
- Pharmacyclics LLC, An Abbvie Company$112
- E.r. Squibb & Sons, L.L.C.$82
- plus $383 from 16 others
Across 61 payments — averaging $5305.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$304K
- Eli Lilly$20K
What the payments were for
- Food & beverage$1,14389%
- Education$13911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 28 | $220 |
| Johnson & Johnson(2 entities) | 3 | $194 |
| Novartis | 10 | $154 |
| Bristol Myers Squibb | 9 | $138 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $112 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Eisai Inc. | 2 | $44 |
| AstraZeneca | 3 | $41 |
| Bayer | 2 | $38 |
| Amgen | 2 | $37 |
| Foundation Medicine, Inc. | 1 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $28 |
| Puma Biotechnology, Inc. | 2 | $26 |
| Sanofi | 1 | $20 |
| Merck | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Seagen Inc. | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $12 |
| Tesaro, Inc. | 1 | $12 |
How this compares
$1,282 in reported general payments places this provider in the 35th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 30 | $744,873 |
| IbrancePalbociclib | 17 | $268,492 |
| Ferriprox (2 Times A Day)Deferiprone | 12 | $255,307 |
| Abiraterone Acetate | 42 | $140,895 |
| EliquisApixaban | 49 | $50,003 |
| OrgovyxRelugolix | 11 | $27,206 |
| XareltoRivaroxaban | 25 | $24,698 |
| Exemestane | 55 | $11,398 |
| Ondansetron Hcl | 83 | $7,857 |
| Anastrozole | 400 | $5,975 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 93 | $1,436 |
| Prochlorperazine Maleate | 98 | $1,053 |
| Potassium Chloride | 41 | $1,036 |
| Letrozole | 49 | $854 |
| Imatinib Mesylate | 13 | $853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $220 | $318,49666 claims |
| Johnson & JohnsonXarelto | $194 | $24,69825 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Kettering
- Mark MarinellaKettering$84K
- David CarboneColumbus$438K
- Elyse LowerCincinnati$312K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Timothy BurnsColumbus$64K
- William TseCleveland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.